AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...

We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...

GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

"2025 was a year that demonstrated Bambusa's execution-first culture," said Dr. Xu. "With multiple clinical programs advancing in parallel, we are entering 2026 positioned to deliver up to 10 clinical ...

USA: Researchers have discovered in a new research that bronchodilator responsiveness (BDR) shows a stronger association with ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that include chronic bronchitis and emphysema. It’s a chronic condition that makes breathing difficult, and can lead to ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. Effective management ...

Cardiovascular diseases and diabetes are some of the most common coexisting conditions in COPD. Shared risk factors and overlapping physiological processes likely contribute to the high rate of ...